Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity ...

Announcing the submission of a marketing application for its experimental weight loss drug, orforglipron, in China, Eli Lilly (LLY) said on Wednesday that it plans to invest $3B in the country over ...

Hims & Hers Health (HIMS) has made a major change in its PR function with the hiring of Kathryn Beiser, who has served Lilly (LLY) as the weight loss drugmaker’s chief communications officer for five ...

SHANGHAI, March 11 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to invest $3 billion in China over the next decade, which will help build production capacity for its experimental ‌type-2 ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Eli Lilly commits $3 billion to China expansion spanning the next ten years Funding targets orforglipron manufacturing, the company’s oral GLP-1 therapy for weight management Marketing authorization ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north of $1,200. The company experienced tremendous growth ...

Add Yahoo as a preferred source to see more of our stories on Google. A screen displays the logo and trading information for Eli Lilly and Company on the floor at the New York Stock Exchange (NYSE) in ...

A common refrain since GLP-1 weight-loss drugs hit the market is that the price of treatments has led many employers to hesitate about providing access to the drugs through company health plans. In ...